Elena Levantini
STAFF
Project
NSCLC-EGFRm-BMI1
Improving therapy response in EGFR mutant lung cancer by targeting transcriptional alterations in tumor and immune cells
Name
Improving therapy response in EGFR mutant lung cancer by targeting transcriptional alterations in tumor and immune cells
Acronym
NSCLC-EGFRm-BMI1
Location
Pisa
Start Date
2022
End Date
2027
Funder
AIRC Investigator Grant
Partners
Universita' di Pisa, IRCCS San Gerardo dei Tintori, University of Alabama Birmingham, Harvard Medical School
The major goal of this project is to investigate the effects of BMI1 inhibition in EGFR-mutant tumors that have developed resistance to osimertinib. Using single-cell RNA sequencing, the project aims to dissect the cellular and transcriptional heterogeneity associated with drug resistance and to identify adaptive mechanisms that may be targeted to overcome therapy failure.
Publications
- Armanetti et al., bioRxiv, 2025 https://www.biorxiv.org/content/10.1101/2025.09.25.678204v1
- Maroni et al., bioRxiv, 2025 https://www.biorxiv.org/content/10.1101/2025.07.04.663159v1
- Maroni et al, bioRxiv, 2025 https://www.biorxiv.org/content/10.1101/2025.06.27.661913v1
- Maroni et al., Cancer Res Commun, 2024 https://doi.org/10.1158/2767-9764.CRC-23-0161
- Levantini, Int J Mol Sci, 2024 https://pubmed.ncbi.nlm.nih.gov/38891765/
- Forini et al., Front Cell Dev Biol, 2024 https://pubmed.ncbi.nlm.nih.gov/39156970/
- Aftab et al., Br J Cancer, 2023 https://pubmed.ncbi.nlm.nih.gov/36810913/
- Levantini, Int J Mol Sci, 2023 https://pubmed.ncbi.nlm.nih.gov/37834107/
- Levantini, Fron Oncol, 2023 https://pubmed.ncbi.nlm.nih.gov/36712496/
- Levantini et al., Semin Cancer Biol., 2022 https://pubmed.ncbi.nlm.nih.gov/35427766/
